Search

Displaying results 5431 - 5440 of 7017 in total
  1. Drug

    Cetrorelix

    go.drugbank.com/drugs/DB00050
    ApprovedInvestigational

    Cetrorelix is a man-made hormone that blocks the effects of Gonadotropin Releasing Hormone (GnRH).

  2. Drug

    Probucol

    go.drugbank.com/drugs/DB01599
    ApprovedInvestigationalWithdrawn

    A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    CY301

    go.drugbank.com/drugs/DB06382
    Experimental

    CY301 (Simplivir) is an investigational gene silencing compound developed by CytoGenix for the treatment of HSV.

  4. Drug

    Apolizumab

    go.drugbank.com/drugs/DB06467
    Investigational

    Apolizumab is a humanized monoclonal antibody that is being studied as a treatment for hematologic cancers.

  5. Drug

    CTX130

    go.drugbank.com/drugs/DB18627
    Investigational

    CTX130 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD70 antigen.

    Synonyms: Allogeneic CRISPR/Cas9-mediated genetically modified CAR T cells targeting CD70 antigen
  6. Drug

    AG-24322

    go.drugbank.com/drugs/DB13035
    Investigational

    AG-024322 has been used in trials studying the treatment of Neoplasms and Lymphoma, Non-Hodgkin.

  7. Drug

    Surotomycin

    go.drugbank.com/drugs/DB12076
    Investigational

    It is a benzenebutanoic acid derivative patented by Cubist Pharmaceuticals, Inc. as antibacterial agents for the treatment of Gram-positive infections. … Surotomycin has a fourfold greater in vitro potency than vancomycin against C.

  8. Drug

    MDX-214

    go.drugbank.com/drugs/DB06110
    Experimental

    It is developed for the treatment of EGF-R overexpressing cancers. … MDX-214 consists of recombinant human epidermal growth factor (EGF) genetically linked to a fully human antibody fragment that is designed to activate cytotoxic killing of cancer cells by immune effector

  9. Drug

    IDD-3

    go.drugbank.com/drugs/DB05427
    Experimental

    It includes Dendritophages that are dendritic cells, a type of specialized immune cells derived from the patient's own white blood cells. … IDD-3 is a therapeutic specific immunostimulant developed by IDM Pharma in partnership with sanofi-aventis. It consists of mature dendritic cells loaded with lysates from melanoma tumor cell lines.

  10. Drug

    4-Phenylfentanyl

    go.drugbank.com/drugs/DB09168
    ExperimentalIllicit

    4-Phenylfentanyl is a sythetic opioid derived from fentanyl. 4-Phenylfentanyl is around 8x the potency of fentanyl in analgesic tests on animals, but more complex 4-heteroaryl derivatives such as substituted … thiophenes and thiazoles are more potent still, as they are closer bioisosteres to the 4-carbomethoxy group of carfentanil.